30.5 C
Vientiane
Saturday, September 13, 2025
spot_img
Home Blog Page 448

Guozi Robotics and TZ Group Build a Flagship End-to-End Intelligent Logistics Project for the Construction-Machinery Sector

HANGZHOU, China, July 29, 2025 /PRNewswire/ — China’s leading smart-manufacturing and intelligent-logistics provider, Guozi Robotics, has successfully delivered a cutting-edge intelligent production and logistics system for TZ Group’s greenfield factory. Nearly 200 robots of diverse types now automate the entire excavator production process and the logistics network, setting a new benchmark for the sector’s digital transformation.

The go-live eliminates long-standing pain points for TZ: high-mix/low-volume production and limited flexibility, by automating every step, from the start of the production to the final outbound shipment.

Production re-engineered: unlocking true flexibility
Guozi installed a multi-robot collaborative ecosystem:

  • Mobile-robot swarms at each station execute precise transfers via dynamic path planning.
  • A matrix of gantry robots, cobots, turnover units and other custom devices performs complex, high-mix operations without re-tooling delays.
  • Contact-free power rails guarantee 24/7 uptime.

Crucially, the project runs on Guozi’s self-developed Line-Side Control System (LCS) and MES, enabling seamless data integration between shop-floor devices and plant management.

Logistics reinvented: centimetre-level orchestration
In the three-dimensional distribution network Guozi created:

  • Materials are classified as large, medium, small and standard parts.
  • ANTS lifting AGVs, PICKING multi-layer robots and heavy-duty carriers automatically interface with racks, pallets and bins.
  • Guozi’s AI-driven RCS coordinates hundreds of AGVs with centimetre-level accuracy, supports multiple call-for-parts modes and pairs dynamic storage with smart picking—offering end-to-end visibility from warehouse to workstation.

Proven experience across the industry
Guozi’s heavy-duty robot family, ANTS and PICKING robots have already driven the smart production in lighthouse factories for Zoomlion, XCMG and Sany worldwide. The TZ Group project is the latest proof of Guozi’s ability to deliver comprehensive, future-ready smart-manufacturing and intelligent-logistics solutions for the construction-machinery industry.

ABOUT Guozi Robotics:
Guozi Robotics is committed to being a top-tier global mobile robotics company, focusing on innovating and applying cutting-edge core mobile robotics technology. Guozi’s product lineup, including intelligent inspection and logistics solutions, positions us as an industry leader in production capacity, product variety, and practical applications

ANTS & heavy-duty robots are operating on-site.
ANTS & heavy-duty robots are operating on-site.

 

Forrester To Recognize AIA Group As Its 2025 Customer-Obsessed Enterprise Award Winner At CX Summit APAC

SINGAPORE, July 29, 2025 /PRNewswire/ — Forrester (Nasdaq: FORR) today announced AIA Group as the winner of its 2025 Customer-Obsessed Enterprise Award for the Asia Pacific region. The award recognizes organizations that drive business success by putting customers at the center of their leadership, strategy, and operations. AIA Group will be honored at CX Summit APAC, being held in Sydney and digitally, on August 18, 2025.

AIA Group, a leading insurance provider in Asia, has been recognized for its successful transformation across 18 markets to deliver a seamless omnichannel digital customer experience. Through cross-functional collaboration, the company standardized its feedback collection process to respond to real-time insights, enhancing customer satisfaction. By reimagining customer journeys and interactions with agents and digital platforms, AIA now offers faster, more relevant, and personalized services for its customers.

“At AIA, our commitment to delivering exceptional customer experiences is at the heart of everything we do,” said Biswa Misra, Group Chief Technology and Life Operations Officer, AIA Group. “The EASE program — anchored in the principles of being Empathetic, Automated, Simple, and Engaged — has transformed how we operate. With strong executive sponsorship, agile governance, and customer-centric KPIs embedded at every level, we’ve created a culture where customer obsession drives performance. By leveraging real-time feedback, advanced analytics, and continuous training, we’re not just meeting expectations — we’re setting new standards for excellence in the insurance industry.”

“We congratulate AIA Group for winning Forrester’s Customer-Obsessed Enterprise Award in APAC,” said Dane Anderson, senior vice president of international research and product at Forrester. “The company is a leading example of how to embed customer centricity into every business decision, and not just isolated customer interactions, to drive tangible business success. We look forward to hearing their success story at CX Summit APAC 2025.”

Resources:

About Forrester

Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We empower leaders in technology, customer experience, digital, marketing, sales, and product functions to be bold at work and accelerate growth through customer obsession. Our unique research and continuous guidance model helps executives and their teams achieve their initiatives and outcomes faster and with confidence. To learn more, visit Forrester.com.

NWTN Inc. to Hold 2025 Extraordinary General Meeting on August 12, 2025

DUBAI, UAE, July 29, 2025 /PRNewswire/ — NWTN Inc. (Nasdaq: NWTN) (the “Company” or “NWTN”), a Nasdaq-listed company headquartered in the UAE, today announced that it will hold its 2025 extraordinary general meeting of shareholders (the “Extraordinary General Meeting”) at Office 114-117, Floor 1, Building A1, Dubai Digital Park, Dubai Silicon Oasis, Dubai, UAE on August 12, 2025 at 3 p.m., local time. Shareholders can also participate in the Extraordinary General Meeting, vote, and submit questions via live webcast by visiting https://www.cstproxy.com/nwtn/2025

Holders of ordinary shares of record on the close of business on July 16, 2025 (the “Record Date”) or their proxy holders are entitled to vote at the Extraordinary General Meeting or any adjournment or postponements thereof. As of the Record Date, each Class A ordinary share is entitled to twenty-five votes, and each Class B ordinary share is entitled to one vote.

The Company proposed to (i) change the Company’s name from “NWTN Inc.” to “Robo.ai Inc.”, (ii) remove independent directors Alain Batty, Joseph Levinson, and Michael S. Cashel, and executive director Aaron Huainan Liao from the board of directors of the Company (the “Board”), (iii) appoint Yehong Ji as a new independent director of the Company, (iv) amend and restate the currently effective Second Amended and Restated Memorandum and Articles of Association of the Company by the deletion in their entirety and by the substitution in their place of the Third Amended and Restated Memorandum and Articles of Association to reflect the change of the Company’s name, and (v) authorize any one director or executive officer of the Company to take any and every action that might be necessary, appropriate or desirable to give effect to the foregoing resolutions as such director or executive officer, in his/her absolute discretion, thinks fit, including but not limited to, attendance on any filing or registration procedures for and on behalf of the Company in the Cayman Islands.

The notice of the extraordinary general meeting sets forth the resolutions to be submitted to shareholders of the Company for approval and other relevant information regarding the extraordinary general meeting and how to vote ordinary shares at the extraordinary general meeting.

INVESTORS AND SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE MATERIALS FILED WITH OR FURNISHED TO THE U.S. SECURITIES AND EXCHANGE COMMISSION, AS THEY CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE CHANGE OF COMPANY NAME, AND RELATED MATTERS.

About NWTN Inc.

NWTN (Nasdaq: NWTN), a UAE-headquartered global intelligent technology company, focuses on smart mobility, smart manufacturing, and smart contracts. By integrating smart manufacturing with its global ecosystem platform, the Group is expanding its smart technology ecosystem across markets including MENA, Southern Europe, and beyond, driving sustainable development through technological innovation.

A Blueprint for Beauty: Meiyume Indonesia’s Interactive Showcase Brings Insights-driven Innovation to Life

HONG KONG, July 29, 2025 /PRNewswire/ — Meiyume, an ODM and OEM leader in the beauty industry, invites beauty brands to explore “Your Beauty Blueprint: From Insights to Impact,” an exclusive private showcase taking place on 5–6 August 2025 at its Indonesia manufacturing plant.

Meiyume - Your Beauty Blueprint: From Insights to Impact
Meiyume – Your Beauty Blueprint: From Insights to Impact

Designed as an interactive experience, the event offers beauty brands a firsthand look at Meiyume’s latest insights-led innovations across colour, skincare, bodycare, and more — powered by the Beauty Intelligence Platform (BIP). Attendees will explore Meiyume’s end-to-end capabilities in formulation, packaging, and turnkey manufacturing through trend presentations, live demos, and expert-led conversations.

2025 Innovation Collection:

Meiyume will introduce four targeted ranges designed to meet the evolving needs of beauty consumers across Southeast Asia — each thoughtfully crafted using trending ingredients and emerging claims identified through Meiyume’s BIP. These collections offer brands a springboard to develop relevant, on-trend products that meet today’s market expectations and consumer desires.

  1. Intercos x Meiyume: A curated range of trend-driven colour and skincare innovations, this collection marks the first official showcase since the strategic alliance between Intercos and Meiyume earlier this year. Featuring Halal-compliant, sensorial formulas, it is thoughtfully crafted for the Southeast Asian beauty consumer.
  2. Longevity: This targeted skincare range combines cutting-edge biotech with gentle, skin-compatible innovation to strengthen the skin barrier, promote resilience, and preserve a natural, radiant glow—before the first signs of ageing appear.
  3. NovaTouch: This thoughtfully developed body care collection is designed to support women through pregnancy and postpartum, combining science-backed and natural ingredients to deliver both safety and performance.
  4. BloomTots: This gentle, science-backed skincare and haircare range for babies and young children supports microbiome balance, barrier repair, and daily protection against environmental stressors.

The showcase also features GAIA, Meiyume’s latest packaging innovation that merges sophistication with sustainability, and HORISUN, a curated selection of trend-driven suncare packaging solutions. These collections are part of Meiyume’s library of stock innovations, each ready for customisation and commercialisation.

Beauty Intelligence Platform (BIP):

Meiyume’s 2025 ODM collection is guided by its proprietary BIP — a sophisticated AI system that analyses real-time data across product, packaging, and ingredient trends. This ensures every formulation is insight-led, relevant, and aligned with evolving consumer demands.

A Blueprint for Innovation

This is more than a product unveiling — it’s an immersive journey into Meiyume’s world of end-to-end beauty innovation. Through live demonstrations, expert presentations, and optional guided tours, attendees will experience how Meiyume supports brands from insight to execution.

From discovering the direction with data-led insights, to building the solution with trend-driven formulation and packaging, to powering the production through their global manufacturing network — this showcase invites beauty brands to envision how their next breakthrough can take shape.

Whether launching a new line or expanding an existing one, Meiyume invites brands to explore how we can bring their next beauty breakthrough to life. Interested visitors are invited to contact Meiyume for more information or to RSVP.

About Meiyume:

Meiyume is a global OEM, ODM and packaging leader in the beauty industry, providing smart end-to-end solutions that drive success for brands. With a focus on sustainability, innovation, and quality, Meiyume delivers exceptional value to beauty brands, big or small.

https://meiyume.com/
Jl. Raya Bogor KM 28, Jakarta 13710, Indonesia

Game On! Tencent Cloud’s EdgeOne Hackathon Is Here

Nearly US$20,000 Prize Pool and 100 Exclusive Rewards for Top Developers

Participants use Tencent Cloud EdgeOne to develop games; finalists to showdown for a 24-hour hackathon at Tencent‘s HQ in Shenzhen

SHENZHEN, China, July 29, 2025 /PRNewswire/ — Tencent Cloud, the cloud business of global leading technology company Tencent, today announced the launch of its EdgeOne Global Game Hackathon – a competition designed to ignite creativity and technical innovation among developers. Under the theme “SplitSecond Spark“, participants will embark on a serverless development challenge to develop lightweight web games using Tencent Cloud’s EdgeOne platform.

Tencent Cloud EdgeOne Global Game Hackathon
Tencent Cloud EdgeOne Global Game Hackathon

Tencent Cloud is the engine behind some of the world’s most popular and demanding online gaming experiences, such as Honor of Kings, Reverse 1999 and others, serving hundreds of millions of players across the globe in real-time. The hackathon draws upon this legacy, giving amateur developers and emerging talent the opportunity to build their own games using the same scalable infrastructure and powerful tools trusted by top game studios.

Unleashing Creativity Through a Unique Hackathon Experience

Open to participants globally, the EdgeOne Global Game Hackathon unfolds in two phases. The competition will undergo a first online preliminary round, followed by a second phase where finalists will be invited to Tencent’s headquarters in Shenzhen, China, for an in-person final round featuring a live pitch session. Participants are encouraged to form a team of up to three people. This format allows developers to showcase their creativity and technical skills while engaging with a global community of like-minded creators.

More than just a contest, the hackathon serves as a launchpad for growth, recognition, and connection within the global game development community. With a prize pool of nearly US$20,000 for the best game, the EdgeOne Global Game Hackathon offers a unique platform to showcase creativity, sharpen technical skills, and accelerate careers in the ever-evolving world of gaming.

Focusing on Immersive Web Game Experiences

During the online round, participants will design original web-based games using Tencent Cloud EdgeOne, a one-stop edge security acceleration platform. With EdgeOne, developers can easily build imaginative, high-performance games in a browser-native environment, enjoying fast loading, global reach, and worry-free security and acceleration services.

The challenge focuses on creating lightweight web-based games that focuses on web game experiences, where players interact with the environment or NPCs. Submissions will be evaluated based on creative design, storytelling, technical implementation of EdgeOne, and overall gameplay engagement. Developers are encouraged to explore a wide range of genres such as casual puzzles, action-adventure, strategy, and narrative-driven games. By emphasizing web-gameplay, the hackathon invites participants to craft simple yet immersive experiences that resonate deeply with players around the world.

Innovating with Popular Game IPs

Finalists will be invited to Shenzhen in September to compete in the final round. They will be challenged with reimagining globally popular game IPs through technical reconstruction and artistic reinterpretation. In just 24 hours, they will develop a lightweight web game, such as a casual mini-game, side story interaction or puzzle, based on selected IPs, showcasing their ability to blend storytelling with innovative gameplay.

Key Dates

Dates

Items

Now – August 11

Registration, development, and submission of projects

August 11

Submission Deadline

August 12 – August 17

YouTube popularity metrics deadline

August 19 – August 21

Announcement of finalists

September 15-18

In-person final round at Tencent Global Digital Ecosystem Summit 2025

Developer Carnival

Register today for the Tencent Cloud EdgeOne Global Game Hackathon and let your imagination run wild!

For more information and to sign up, visit here.

END

About Tencent Cloud

Tencent Cloud, one of the world’s leading cloud companies, is committed to creating innovative solutions to resolve real-world issues and enabling digital transformation for smart industries. Through our extensive global infrastructure, Tencent Cloud provides businesses across the globe with stable and secure industry-leading cloud products and services, leveraging technological advancements such as cloud computing, Big Data analytics, AI, IoT, and network security. It is our constant mission to meet the needs of industries across the board, including the fields of gaming, media and entertainment, finance, healthcare, property, retail, travel, and transportation.

Vinmec Central Park Performs Vietnam’s First SEEG using AutoGuide Robotic Guidance System for a child diagnosed from refractory epilepsy

HO CHI MINH CITY, VIETNAM – Media OutReach Newswire – 29 July 2025 – A major breakthrough in Vietnam’s neurological treatment was recently achieved as doctors at Vinmec Central Park International Hospital successfully performed surgery on a 9-year-old boy with drug-resistant epilepsy, utilizing the AutoGuide™ robotic Guidance system for SEEG implantation.

The patient recovered quickly after surgery.
The patient recovered quickly after surgery.

This marks the first time in Vietnam that robotic guidance has been used in pediatric epilepsy surgery, — a milestone that opens new possibilities for safer, less invasive, and highly precise treatment options for vulnerable patients. The case also highlights Vietnam’s progress in approaching global standards in advanced epilepsy care.

A 5-Year Search for Seizure-Free Sleep

The patient, B.Q.K. (age 9, from Hanoi), began experiencing seizures in 2021. Despite various treatment regimens and adjustments both domestically and abroad, his condition failed to improve – sometimes experiencing dozens of seizures per day.

For nearly five years, his family sought treatment at numerous medical centers in the hope of giving their child a peaceful night’s sleep without seizures.

According to the World Health Organization (WHO), approximately 30% of epilepsy patients are drug-resistant (1), meaning they do not respond to medication. For these patients, surgery resection of the epileptic zone is often the most effective option. However, accurately localizing the epileptogenic zone – especially in children – is extremely challenging when scalp EEG, MRI, or PET scans provide inconclusive findings.

SEEG and AutoGuide: A Technological Duo to Precisely Locate the “Culprit” in the Brain

Following a thorough multidisciplinary evaluation, doctors at Vinmec Central Park decided to use AutoGuide™ robotic navigation system to perform stereo-electroencephalography (SEEG) to accurately identify the epileptic zone. The robotic guidance ensured high accuracy, faster operative time, and reduced trauma to the brain.

After seven days of SEEG monitoring, the epileptogenic zone was localized in the right orbitofrontal cortex and inferior frontal gyrus—areas densely packed with neural pathways and blood vessels. On June 17, 2025, the epileptic zone removal was performed by Dr. Truong Van Tri and his team at Vinmec Central Park, with technical support from Assoc. Prof. Dr. Shunsuke Nakae, an epilepsy specialist from Japan.

The surgery was successful, with no postoperative neurological deficits. After more than one month of recovery, the patient resumed normal activities and play, with only two minor nocturnal seizures recorded – a reduction of over 95% compared to preoperative frequency.

For the first time, we achieved near-perfect outcome in pediatric epilepsy surgery thanks to AutoGuide™. This is a critical milestone, especially for young patients who are highly vulnerable to major brain surgery,” said Dr. Tri.

Vinmec: Advancing Neurology with Technology and International Integration

This successful case exemplifies Vinmec’s strategy to build centers of medical excellence through the integration of advanced technology, multidisciplinary expertise, and individualized treatment protocols. Vinmec has been ranked as the No.1 private hospital system in Vietnam for expatriates and international visitors, according to independent patient satisfaction surveys.

Vinmec Central Park is currently one of the few healthcare facilities in Vietnam, placing Vietnam among the few countries in Asia to master this technique—narrowing the gap with global neurology leaders.

(1) https://www.who.int/docs/default-source/mental-health/mhgap/epilepsy-and-seizures/epilepsy-q15.pdf

Hashtag: #Vinmec

The issuer is solely responsible for the content of this announcement.

About Vinmec Health System

Vinmec is a nonprofit healthcare system founded by Vingroup, one of Vietnam’s largest private conglomerates. With 9 international hospitals and 4 international clinics nationwide, Vinmec is committed to delivering international-standard healthcare through subspecialized care, personalized treatment, and cutting-edge medical technology.

Vinmec Central Park in Ho Chi Minh City is the flagship hospital in the network and has been widely recognized as the top private hospital in Vietnam for expatriates and international patients, serving tens of thousands annually.

The hospital excels across several specialties:

  • Neurosurgery & Epilepsy: SEEG, robotic-guided surgery, brain tumor resection
  • Oncology – Orthopedic Surgery – Cardiology – Advanced Obstetrics & Gynecology
  • Allergy & Clinical Immunology: Vietnam’s first and only center recognized as a Center of Excellence by the World Allergy Organization (WAO), in close partnership with Cleveland Clinic (USA) to develop precision medicine and chronic disease management programs
  • 3D Medical Technology: Pioneer in 3D-printed titanium implants for complex orthopedic oncology reconstructions

Toasting the world in Laoshan: A summer of beer, culture, and celebration

QINGDAO, China, July 29, 2025 /PRNewswire/ — A news report from China Daily:

Locals and tourists flock to the "Beer Exchange", a newly launched special event at the Laoshan venue of the 35th Qingdao International Beer Festival in Shandong province on July 22. Customers serve themselves with cups, scan QR codes to purchase beers, while a dynamic system adjusts beer prices in real time, just like that of a stock exchange. (Photo by ZHANG JINGANG /FOR CHINA DAILY)
Locals and tourists flock to the “Beer Exchange”, a newly launched special event at the Laoshan venue of the 35th Qingdao International Beer Festival in Shandong province on July 22. Customers serve themselves with cups, scan QR codes to purchase beers, while a dynamic system adjusts beer prices in real time, just like that of a stock exchange. (Photo by ZHANG JINGANG /FOR CHINA DAILY)

The Laoshan venue of the ongoing 35th Qingdao International Beer Festival, running through August 16, invites guests from around the world to experience a wonderful summer celebration of global beer, food, culture, and fun in Laoshan district of the coastal city of Qingdao, Shandong province.

This year, the Laoshan venue features a unique “dual-style” layout—known as Yicheng Shuangjing—offering both Chinese and European-themed experiences respectively at its central and southern part of the Century Square Beer City. Visitors can explore creative activities, cultural performances, specialty food streets, and exhibitions of cultural and creative products.

Beer lovers are treated to 93 types of brews from 18 brands across 11 countries. The venue has launched themed days for international guests, special discount packages, and tailored travel routes. To ensure a smooth and inclusive experience, multilingual signage and interpretation services are available in Chinese, English, Japanese, and Korean. Printed guides, including the Laoshan District Cultural Tourism Guide and Top 10 Laoshan Travel Routes, are also available in multiple languages.

One highlight is the creative “Trendy Play” zone, an interactive area featuring VR experiences, a national-level jump rope challenge, traditional Chinese performance arts, and roaming NPCs (non-player characters) for added immersion. The venue also integrates business-focused elements, offering private reception spaces and organizing themed days around talent, finance, and technology, alongside exclusive events for companies and media, creating a platform for both entertainment and networking.

Visitors can enjoy an authentic cultural experience in the “Elegant Chinese Style” zone at the central part of the Laoshan venue, which includes an ancient-style tavern, a Laoshan-themed cultural store, and a beer festival exhibition. Meanwhile, the venue’s southern part features the “Fashionable European Charm” zone, presenting pop-up street performances and European-style shows for a fully immersive experience.

Food lovers can indulge in the “Craving Street, Tipsy Alley” area, a bustling street market featuring both Chinese delicacies and European cuisine. Local specialties and international bites are all part of the mix. The venue also debuts Laoshan’s first Beer Exchange, where visitors can enjoy 360-degree self-serve beer taps—creating a new social media hotspot.

Seven beer gardens, including the Tsingtao 1903 Bar and the Draft Beer Garden, add to the lively atmosphere. More than 30 events, from exclusive coupons to joint promotions with local beer-themed homestays, bring a down-to-earth flavor to the beer fest full of local charm.

As the 35th Qingdao International Beer Festival hits full swing, the Laoshan venue stands out for its mix of mountain and sea beauty, urban innovation, and global joy. This summer, let’s gather in Qingdao, raise our glasses in Laoshan district, and toast to a world united by beer.

Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Obtained Orphan Drug Designation from the U.S. FDA for the Treatment of GC/GEJ

SUZHOU, China, July 29, 2025 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer and gastroesophageal junction cancer (GC/GEJ).

GC/GEJ is the fifth most common cancer and the fifth leading cause of cancer death worldwide. According to the 2022 Global Cancer Statistics report released by the International Agency for Research on Cancer (IARC), a subsidiary of the World Health Organization, there are approximately 960,000 new cases diagnosed and 660,000 deaths worldwide annually. In the U.S., the SEER database model predicts that there will be 26,890 new cases and 10,880 new deaths of GC/GEJ in 2024, with a five-year overall survival rate of less than 40%. Fluoropyrimidine and platinum-based regimens are commonly used as first-line treatments. Available second-line or later-line treatment options include paclitaxel plus ramucirumab, paclitaxel, docetaxel or irinotecan monotherapy, and best supportive care, with objective response rates of approximately 15-25%. The median overall survival is approximately 8-9 months for second-line treatment and 4-6 months for later lines.

JSKN003 is an anti-HER2 biparatopic ADC developed inhouse with Alphamab’s proprietary glycan-specific conjugation platform. The antibody molecule KN026 is site-specifically modified via enzyme catalytic reaction and click chemistry to achieve a drug-to-antibody ratio (DAR) of approximately 4. It can bind HER2 on the surface of tumor cells, and release topoisomerase I inhibitors (TOPIi) through cellular endocytosis, thereby exert anti-tumor effects. Compared with its ADC counterparts, JSKN003 demonstrated better serum stability and stronger bystander effect, which effectively expands the therapeutic window. Research results from the Phase I clinical study JSKN003-101 (NCT05494918) conducted in Australia and the Phase I/II clinical study JSKN003-102 (NCT05744427) in China have demonstrated favorable tolerability and safety profile, with promising efficacy of JSKN003 in heavily pretreated patients with advanced solid tumors, especially in patients with high HER2-expressing gastrointestinal tumors. Detailed data were presented at the 2024 European Society for Medical Oncology (ESMO) Congress for the first time and subsequently updated at the 2025 Annual Meeting of American Society of Clinical Oncology (ASCO) in June 2025.

The “Orphan Drug Designation”, originated from the Orphan Drug Act (ODA), is a U.S. FDA initiative aimed at encouraging the development of innovative drugs for the treatment of diseases affecting fewer than 200,000 people in the U.S. The designation of JSKN003 will be beneficial to obtain relevant policy supports for subsequent research and development, registration, and commercialization in the U.S., including funding for research and development costs, tax credits for clinical trial expenditures, waiver of prescription drug user fee, accelerated review and approval processes, and, upon approval, the potential for seven years of market exclusivity in the U.S.

About JSKN003

JSKN003 is a bispecific ADC developed based on KN026 using Alphamab’s proprietary glycan-specific conjugation platform. JSKN003 can bind HER2 on the surface of tumor cells and release topoisomerase I inhibitors (TOPIi) through cellular endocytosis, thereby exerting anti-tumor effects. Compared with its ADC counterparts, JSKN003 demonstrated better serum stability and stronger bystander effect, which effectively expands the therapeutic window.

Results of multiple clinical studies at various stages of JSKN003 in China and Australia have demonstrated favorable safety profile, with promising efficacy of JSKN003 in heavily pretreated patients with advanced solid tumors, especially in patients with platinum-resistant ovarian cancer (PROC), HER2-expressing breast cancer (BC), or high HER2-expressing solid tumors. JSKN003 was granted breakthrough therapy designation by CDE. The designation is for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. Three Phase III clinical studies of JSKN003 for the treatment of HER2-low expressing BC, PROC, and HER2-positive BC as well as multiple exploratory Phase II clinical studies are currently undergoing smoothly.

In September 2024, the Company entered a licensing agreement with JMT-Bio Technology Co., Ltd. (“JMT-Bio”), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (“CSPC”) (stock code: 1093.HK), pursuant to which, JMT-Bio was granted the exclusive license and sublicense rights to develop, sell, offer for sale and commercialize JSKN003, for the treatment of tumor-related indications (the “Field”) in mainland China (excluding Hong Kong, Macau or Taiwan) (the “Territory”) and become the sole marketing authorization holder for JSKN003 for the Field in the Territory. Alphamab retains the sole right to supply JSKN003.

About Alphamab Oncology

Alphamab Oncology is an innovative biopharmaceutical company focusing on oncology therapeutics. On December 12, 2019, the Company was successfully listed on the Main Board of the Hong Kong Stock Exchange, trading under the stock code 9966.

By leveraging its proprietary core technology platforms including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payload, dual-payload antibody conjugation, and subcutaneous high concentration formulation for biologics, the Company has established a product portfolio with differentiated innovation and global competitiveness, covering cutting-edge areas such as antibody-drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies.

The Company has one product approved for marketing (Envafolimab, the world’s first subcutaneously injectable PD-(L)1 inhibitor), which has made a significant breakthrough in the convenience and accessibility of cancer treatment. Additionally, the Company has multiple bispecific antibodies and bispecific ADCs in clinical stage, while rapidly advancing the preclinical pipeline prioritizing bispecific ADCs and dual-payload ADCs. Multiple strategic collaborations based on innovative products or technology platforms have been established with partners such as CSPC, ArriVent, and Glenmark.

Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide.